细胞膜向的J聚合策略,用于协同免疫检查点退化和免疫性烧死,以增强瘤免疫疗法
Xiaona Xu1, Hao Zhang1, Yahui Cao1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Key Laboratory of Functional Polymer Materials of Ministry of Education, Nankai University, Tianjin, 300071, P.R. China.
这项研究引入了一种新的J-聚合物系统,可以降解PD-L1并通过光动力学疗法激活免疫反应,从而提高癌症免疫疗法的有效性,即使在缺氧瘤中也是如此.
科学领域:
- 生物医学工程 生物医学工程
- 癌症研究 癌症研究
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点阻塞 (ICB) 疗法显示出希望,但面临PD-L1循环和免疫抑制瘤微环境等局限性.
- 非目标效应和在低氧条件下有限的疗效阻碍了当前的癌症免疫疗法.
研究的目的:
- 开发一种新的单元系统,用于协同免疫检查点退化和光控制免疫激活.
- 克服当前免疫疗法的局限性,包括PD-L1循环和缺氧.
主要方法:
- 一种PD-L1连接剂-染料结合物被设计成可以自组装成J聚合物,以增强NIR吸收和光动力学活性.
- J-聚合物系统针对瘤细胞膜上的PD-L1,在NIR照射时诱导溶酶体降解和随后的烧灭.
- 药物自我递送能力被整合,利用EPR效应和积极向增强瘤积累.
主要成果:
- 该J-聚合物系统有效地降低了PD-L1水平,并诱导了强烈的,耐低氧耐受性免疫性质的灭.
- 高瘤选择性积累 (高达9.8%ID/g) 是通过积极向和EPR效应实现的.
- 在体内研究表明,有协同的抗瘤免疫反应.
结论:
- 这种针对细胞膜的新型J聚合策略为联合免疫检查点降解和光动力学疗法提供了一个多功能平台.
- 该系统显示了促进癌症免疫治疗的巨大潜力,特别是在具有挑战性的缺氧瘤环境中.
- 这种方法可以适应针对各种膜蛋白,为下一代免疫疗法铺平道路.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
